Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RPRX
stocks logo

RPRX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
829.22M
+11.76%
1.313
+14.09%
825.00M
-1.67%
1.160
+9.73%
714.00M
-1.79%
1.310
+14.85%
Estimates Revision
The market is revising Upward the revenue expectations for Royalty Pharma plc (RPRX) for FY2025, with the revenue forecasts being adjusted by 0.68% over the past three months. During the same period, the stock price has changed by 8.54%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.68%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.43%
In Past 3 Month
Stock Price
Go Up
up Image
+8.54%
In Past 3 Month
Wall Street analysts forecast RPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPRX is 43.80 USD with a low forecast of 38.00 USD and a high forecast of 54.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast RPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPRX is 43.80 USD with a low forecast of 38.00 USD and a high forecast of 54.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 39.150
sliders
Low
38.00
Averages
43.80
High
54.00
Current: 39.150
sliders
Low
38.00
Averages
43.80
High
54.00
TD Cowen
TD Cowen
Buy
to
Hold
downgrade
2025-11-17
Reason
TD Cowen
TD Cowen
Price Target
2025-11-17
downgrade
Buy
to
Hold
Reason
TD Cowen downgraded Royalty Pharma to Hold from Buy without a price target after the company agreed to be acquired by XenoTherapeutics for an estimated $1.82 per share. TD sees little risk to the deal closing.
Goldman Sachs
NULL
to
Buy
initiated
$42
2025-09-30
Reason
Goldman Sachs
Price Target
$42
2025-09-30
initiated
NULL
to
Buy
Reason
Goldman Sachs initiated coverage of Royalty Pharma with a Buy rating and $42 price target, which represents 20% upside. The company offers investors a way to gain exposure to a portfolio of biopharma royalty streams without incurring biotech's "volatility and binary risks," the analyst tells investors in a research note. The firm believes Royalty is in the early stages of a portfolio expansion that is underappreciated in the context of a large, growing total addressable market for royalty funding.
Citi
Buy
maintain
$40 -> $42
2025-07-22
Reason
Citi
Price Target
$40 -> $42
2025-07-22
maintain
Buy
Reason
Citi raised the firm's price target on Royalty Pharma to $42 from $40 and keeps a Buy rating on the shares as part of a Q2 earnings preview for the biotechnology group. The firm says Q2 is typically seasonally strong for the large biopharma names.
Morgan Stanley
Terence Flynn
Overweight
maintain
$51 -> $54
2025-07-10
Reason
Morgan Stanley
Terence Flynn
Price Target
$51 -> $54
2025-07-10
maintain
Overweight
Reason
Morgan Stanley analyst Terence Flynn raised the firm's price target on Royalty Pharma to $54 from $51 and keeps an Overweight rating on the shares. Year-to-date, large cap pharma and biotech companies have both underperformed given the macro environment, while multiple areas of policy uncertainty remain, including drug pricing dynamics, tariff and transfer pricing exposure, and FDA staffing changes, the analyst tells investors in a research note.
Morgan Stanley
Overweight
initiated
$51
2025-05-16
Reason
Morgan Stanley
Price Target
$51
2025-05-16
initiated
Overweight
Reason
Morgan Stanley resumed coverage of Royalty Pharma with an Overweight rating and $51 price target. The firm cites se the company's diversified portfolio and insulation from potential tariffs, coupled with a growth profile above the peer average, as positives.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Royalty Pharma PLC (RPRX.O) is 7.91, compared to its 5-year average forward P/E of 9.93. For a more detailed relative valuation and DCF analysis to assess Royalty Pharma PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
9.93
Current PE
7.91
Overvalued PE
13.14
Undervalued PE
6.72

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
10.32
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
12.39
Undervalued EV/EBITDA
8.24

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.97
Current PS
0.00
Overvalued PS
7.38
Undervalued PS
4.56
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 100.83% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

RPRX News & Events

Events Timeline

(ET)
2025-12-04
07:20:00
Royalty Pharma and Denali Sign $275M Synthetic Royalty Funding Agreement
select
2025-12-04
07:10:00
Denali Therapeutics and Royalty Pharma Announce $275 Million Synthetic Royalty Funding Agreement
select
2025-11-07 (ET)
2025-11-07
09:38:39
Royalty Pharma Executes Block Trade of 14.244 Million Shares at $40.00 Each
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
12-04NASDAQ.COM
Denali and Royalty Pharma Sign $275 Million Royalty Financing Deal

  • Funding Agreement: Denali Therapeutics and Royalty Pharma have entered a $275 million synthetic royalty funding agreement related to the investigational therapy Tividenofusp alfa, aimed at treating mucopolysaccharidosis type II (Hunter syndrome).

  • FDA Review and Payments: The agreement is contingent on Denali obtaining FDA accelerated approval for Tividenofusp alfa, with Royalty Pharma making an initial payment of $200 million and a potential additional $75 million upon European approval by 2029.

  • Royalty Terms: Royalty Pharma will receive a 9.25% royalty on worldwide net sales of Tividenofusp alfa, which will cease once a multiple of 3.0x is reached, or 2.5x if achieved by early 2039.

  • Designations and Market Response: Tividenofusp alfa has received Fast Track and Priority Medicines designations from the FDA and EMA, respectively, and shares of Denali and Royalty Pharma saw slight increases following the announcement.

[object Object]
Preview
7.5
12-04Globenewswire
Royalty Pharma Secures $275M Synthetic Royalty Agreement with Denali for Tividenofusp Alfa
  • Funding Agreement Established: Royalty Pharma has signed a $275 million synthetic royalty funding agreement with Denali based on future net sales of tividenofusp alfa, reflecting strong confidence in this innovative therapy.
  • Accelerated Approval Outlook: The Biologics License Application for tividenofusp alfa is under review by the FDA, with a target date of April 5, 2026, which will significantly bolster Denali's market prospects.
  • Initial Payment Structure: Royalty Pharma will make an initial payment of $200 million at closing and an additional $75 million upon EMA approval of tividenofusp alfa, facilitating Denali's advancement of its development programs.
  • Global Sales Rights: Royalty Pharma will receive a 9.25% royalty on worldwide net sales of tividenofusp alfa, which is expected to provide a stable cash flow for future revenue growth while supporting Denali's product commercialization efforts.
[object Object]
Preview
7.5
12-04Globenewswire
Denali and Royalty Pharma Announce $275 Million Synthetic Royalty Funding Agreement
  • Funding Agreement Established: Denali Therapeutics has signed a $275 million synthetic royalty funding agreement with Royalty Pharma based on future net sales of tividenofusp alfa, reflecting strong confidence in the market potential of this therapy.
  • Accelerated Approval Process: The Biologics License Application for tividenofusp alfa is under review by the FDA, with a target date for accelerated approval set for April 5, 2026, which will provide Denali with crucial market access opportunities.
  • Clear Use of Funds: This financing will be utilized to advance Denali's development programs, particularly supporting the upcoming launch of tividenofusp alfa, thereby enhancing its competitiveness in the rare disease treatment sector.
  • Future Revenue Assurance: Royalty Pharma will make an additional $75 million payment upon receiving EMA approval and will receive a 9.25% royalty on worldwide net sales of tividenofusp alfa, ensuring a shared revenue stream for both parties moving forward.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Royalty Pharma PLC (RPRX) stock price today?

The current price of RPRX is 39.15 USD — it has decreased -1.14 % in the last trading day.

arrow icon

What is Royalty Pharma PLC (RPRX)'s business?

Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 17 development-stage product candidates.

arrow icon

What is the price predicton of RPRX Stock?

Wall Street analysts forecast RPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPRX is 43.80 USD with a low forecast of 38.00 USD and a high forecast of 54.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Royalty Pharma PLC (RPRX)'s revenue for the last quarter?

Royalty Pharma PLC revenue for the last quarter amounts to 609.29M USD, increased 7.90 % YoY.

arrow icon

What is Royalty Pharma PLC (RPRX)'s earnings per share (EPS) for the last quarter?

Royalty Pharma PLC. EPS for the last quarter amounts to 0.67 USD, decreased -44.63 % YoY.

arrow icon

What changes have occurred in the market's expectations for Royalty Pharma PLC (RPRX)'s fundamentals?

The market is revising Upward the revenue expectations for Royalty Pharma plc (RPRX) for FY2025, with the revenue forecasts being adjusted by 0.68% over the past three months. During the same period, the stock price has changed by 8.54%.
arrow icon

How many employees does Royalty Pharma PLC (RPRX). have?

Royalty Pharma PLC (RPRX) has 99 emplpoyees as of December 05 2025.

arrow icon

What is Royalty Pharma PLC (RPRX) market cap?

Today RPRX has the market capitalization of 22.60B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free